“A collaborative strategy”
Developing new genetic variability from a scientific observation to a ready to market product is a long and costly process. We exploit a number of powerful molecular technology and phenotyping platforms, around genomics, genetics, bioinformatics and transgenesis. This broad in-house pipeline generates high-added value tools, and any additional information on our most important traits helps improve the efficiency of our process.
Biogemma is very much in favour of collaborative projects. They bring knowledge and skills to improve our choice of targets and give our partners a stake in adding value to their results. We are and have been involved in numerous collaborations, ranging from almost exclusively scientific work in initiatives like the French Génoplante programme, and its latest form the GIS Green Biotechnology, or EU research projects, to targeted collaborations with biotech companies worldwide aimed at commercial development.